Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
about
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsObesity pharmacotherapy: current perspectives and future directionsEfficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension studyNon-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosisTeneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetesRandomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesDipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of DiabetesSustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetesIncorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitusLinagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes riskManagement of diabetes across the course of disease: minimizing obesity-associated complicationsPharmacokinetics of linagliptin in subjects with hepatic impairmentTherapy in the early stage: incretins.Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.History of current non-insulin medications for diabetes mellitus.Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats.Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the ratPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.A review of gliptins in 2011.Liraglutide: from clinical trials to clinical practice.Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.DPP-4 inhibitors: pharmacological differences and their clinical implications.Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetesEfficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.A Brief History of the Development of Diabetes Medications.Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance.Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
P2860
Q26778608-F7281FA7-6B44-40BB-9D6F-308B3BA94735Q26828559-4C5AC238-55F7-4D0A-B068-C19B2AB1CAE3Q33587818-5BD2F2A5-B35C-450B-B230-3301143F0569Q33646569-B518F005-63C3-40CE-AD27-D83FCD954439Q33646636-2F7BD74A-6E09-4DAD-90EC-3B1327434134Q33688333-6818B7F0-1D6E-4A57-95CD-2E0D24B1EA35Q33706160-13DC185B-4D20-4A92-8AAB-E8C4C6A1A6DFQ33949425-7B88E1B5-ECCE-4D98-99D9-617E8EF80ABAQ34214474-256E09DF-B292-41F3-927D-784AA72B8EC0Q34341759-A840650A-7E73-495C-8BC2-2F8B06094464Q34374336-740BC9A1-6DA5-4337-B70E-BB0D5BF1B2D4Q34496741-DB3E554A-C1D7-48B1-9E6B-CBECD39534CCQ34637776-0CBD79E8-3A55-4046-86A2-80A7631707ABQ35220562-DCEFF286-D711-4B11-828F-CF93DABC93D5Q35574560-9A7A0961-D6E0-40AF-8915-5E349BC8BAFDQ36087961-A5226725-8DFB-4A18-BBAC-0E7DC4C26986Q36783865-34EE98B5-61C9-4BB4-BEB3-9F99B72F2D5CQ36809901-8AAE9FAD-2E02-461F-B33D-7DF1D3D8DF4EQ37021310-40E76C2A-1255-4CD4-BA1D-688C20060B58Q37224352-30032C0F-0EAD-4376-94B2-0F66CCD47EAAQ37275418-30521D9D-EC3F-4DAE-8B9D-D372E510DD09Q37367934-566FACB9-13AF-4AB1-9275-FB20CCE11DAAQ37446672-F8CC9A67-5B72-4B3A-A448-FC6C1E4C66D5Q37735838-AF77FA7D-1D0B-4D5D-B523-12C18FC8A59BQ37875220-163B32D7-D707-4B0F-B534-C3C3B2D35043Q37965612-A0C8187D-EC97-4A14-8F43-4A2E1A08B692Q37992256-5B0F40C0-B4D6-4ED0-8410-48FB2D043968Q38008005-4563C39B-03D4-4455-91E6-8B83369AE00BQ38113093-EDA24A7C-0355-46EC-9423-CFAC0144A603Q38244576-7557A30E-086B-4482-838F-4A0AB0F78330Q38295321-C276DA54-0887-45A0-8A8D-158F1AAFFF47Q38751579-E71B82E6-1AA0-4931-A89D-DB3B8EEC6DDDQ39066626-94EE925C-BEF6-4ED7-86FD-2628912E4AF4Q40757945-43915382-0DEE-4BE2-83F8-D6A11D1D7CF2Q42411664-4DFEE10C-7BE1-4A0D-A49B-6198A8E4D35EQ43853440-70A279E4-EF6B-4074-B714-7A3B6738694AQ48109404-2546AE4F-9C1C-432C-9ECA-7613F70FABA3Q51299689-CE12492A-4E27-4DB3-813B-7B45FF989D95Q51316002-426B643A-53C9-4207-8CD8-0249A5C97EA4Q51370454-38C50E0C-B0BE-427B-AA7E-B832690195D7
P2860
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@ast
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@en
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@nl
type
label
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@ast
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@en
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@nl
prefLabel
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@ast
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@en
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@nl
P356
P1476
Differential chemistry (struct ...... agonists and DPP-4 inhibitors.
@en
P2093
Joshua J Neumiller
P304
P356
10.1331/JAPHA.2009.09078
P478
49 Suppl 1
P577
2009-09-01T00:00:00Z